• 1
    Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev 2007; 87: 14091439.
  • 2
    Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al . Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 19631972.
  • 3
    Green J, Feinglos M. Update on Type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract 2007; 61: 311.
  • 4
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes. Lancet 2006; 368: 16961705.
  • 5
    Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ et al . Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000; 43: 16641669.
  • 6
    Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45: 195202.
  • 7
    Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP et al . Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy, significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with Type 2 diabetes. Diabetes Care 2007; 30: 16081610.
  • 8
    Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007; 30: 20322033.
  • 9
    Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K et al . Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152156.
  • 10
    Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V et al . One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with Type 2 diabetes. Diabetes 2004; 53: 11871194.
  • 11
    American Association of Clinical Endocrinologists. Medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: 168.
  • 12
    International Diabetes Federation. Global Guideline for Type 2 Diabetes. Brussels: International Diabetes Federation, 2005. Available at Last accessed 12 June 2008.
  • 13
    American Diabetes Association. Standards of medical care in diabetes—2008. Diabetes Care 2008; 31: S12S54.
  • 14
    Nauck MA, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH et al . Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in Type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 8490.
  • 15
    Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic SS et al . Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulphonylurea in Type 2 diabetes. Diabetes 2008; 57: P536.
  • 16
    Garber A, Henry R, Ratner R, Garcia-Hernadez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al . Liraglutide versus glimepiride monotherapy for Type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473481.
  • 17
    Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with Type 2 diabetes. Diabetes Care 2004; 27: 26282635.
  • 18
    Russell-Jones D, Vaag A, Schmitz O, Sethi B, Lalic NM, Antic S et al . Significantly better glycaemic control/weight reduction with human GLP-1 analogue liraglutide, than with insulin glargine: all as add-on to metformin + sulphonylurea in Type 2 diabetes. Diabetologia 2008; 51: S68.
  • 19
    Zinman B, Gerich J, Buse J, Lewin A, Schwartz SL, Raskin P et al . Effect of the GLP-1 analogue liraglutide on glycaemic control and weight reduction in patients on metformin and rosiglitazone: a randomized double-blind placebo-controlled trial. Diabetologia 2008; 51: S359.
  • 20
    Blonde L, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett J et al . Liraglutide: superior glycemic control vs exenatide when added to metformin and/or SU in Type 2 diabetes. Can J Diabetes 2008; 32: Abstract 107.
  • 21
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with Type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007; 9: 733745.
  • 22
    Egan JM, Meneilly GS, Elahi D. Effects of 1-mo bolus subcutaneous administration of exendin-4 in Type 2 diabetes. Am J Physiol Endocrinol Metab 2003; 284: E1072E1079.